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Abstract
Background: Epidemiological studies indicate that some characteristics of lung cancer among never-smokers
significantly differ from those of smokers. Aberrant promoter methylation and mutations in some oncogenes and
tumor suppressor genes are frequent in lung tumors from smokers but rare in those from never-smokers. In this
study, we analyzed promoter methylation in the ras-association domain isoform A (RASSF1A) and the death-associated
protein kinase (DAPK) genes in lung tumors from patients with primarily non-small cell lung cancer (NSCLC) from
the Western Pennsylvania region. We compare the results with the smoking status of the patients and the
mutation status of the K-ras, p53, and EGFR genes determined previously on these same lung tumors.
Methods: Promoter methylation of the RASSF1A and DAPK genes was analyzed by using a modified two-stage
methylation-specific PCR. Data on mutations of K-ras, p53, and EGFR were obtained from our previous studies.
Results: The RASSF1A gene promoter methylation was found in tumors from 46.7% (57/122) of the patients and
was not significantly different between smokers and never-smokers, but was associated significantly in multiple
variable analysis with tumor histology (p = 0.031) and marginally with tumor stage (p = 0.063). The DAPK gene
promoter methylation frequency in these tumors was 32.8% (40/122) and did not differ according to the patients'
smoking status, tumor histology, or tumor stage. Multivariate analysis adjusted for age, gender, smoking status,
tumor histology and stage showed that the frequency of promoter methylation of the RASSF1A or DAPK genes did
not correlate with the frequency of mutations of the K-ras, p53, and EGFR gene.
Conclusion: Our results showed that RASSF1A and DAPK genes' promoter methylation occurred frequently in
lung tumors, although the prevalence of this alteration in these genes was not associated with the smoking status
of the patients or the occurrence of mutations in the K-ras, p53 and EGFR genes, suggesting each of these events
may represent independent event in non-small lung tumorigenesis.
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Background
Lung cancer, the leading cause of cancer-related death in
the Unites States and worldwide, is strongly associated
with tobacco smoke exposure [1]. In spite of extensive
studies, the etiology of lung cancer remains poorly under-
stood. Particularly, studies of lung cancer among never-
smokers are few and little is known about the etiology of
lung cancer in never-smoking patients. Some studies
showed that the frequencies and/or patterns of genetic
and epigenetic alterations in some genes in lung tumors
from smokers differ from those in never-smokers. For
instance, mutations in the K-ras oncogene, p53 tumor sup-
pressor gene, and epidermal growth factor receptor
(EGFR) gene have been found frequently in lung tumors
and implicated in lung tumorigenesis. However, while K-
ras  mutations were detected primarily in lung tumors
from smokers [2-4], the EGFR  mutations were found
mostly in lung tumors from never-smokers [5-7]. Further-
more, although the p53 mutations were detected in lung
tumors from both smokers and never-smokers, the muta-
tion types and spectra were different between the two
groups of lung cancer patients [3,8].
In addition to mutations in oncogenes and tumor sup-
pressor genes, results from previous studies demonstrated
that promoter methylation of some genes occurred more
frequently in lung tumors from smokers, compared with
never-smokers [9-13]. Other genes whose transcription
has been found frequently inactivated in lung tumors
include the ras-association domain isoform A (RASSF1A)
and the death-associated protein kinase (DAPK) genes, but
the effects of tobacco smoking on the prevalence of pro-
moter methylation of these genes in lung tumors remain
unclear. The RASSF1 gene is located at 3p21.3 and func-
tions as a tumor suppressor gene involved in cell apopto-
sis, genomic and microtubule stability, and cell cycle
regulation [14]. This gene codes for two major transcripts,
RASSF1A and RASSF1C, by alternative splicing [15,16].
Promoter methylation of the RASSF1A  gene has been
found in many human tumors, including those of the
lung where it was detected in 30% to 50% of non-small
cell lung cancer (NSCLC) [16,17]. The DAPK  gene is
located on chromosome 9p34.1. It encodes for a Ca+/cal-
modulin-regulated serine/threonine kinase involved in
apoptosis induced by interferon-γ, tumor necrosis factor
α, activated Fas, transforming growth factor β, ceramide
and detachment of cells from the extracellular matrix [18].
DAPK suppresses tumor growth by increasing the occur-
rence of apoptosis [19]. Expression of DAPK is frequently
lost in many human cancers, often as a result of silencing
by DNA methylation. Promoter methylation of the DAPK
gene has been found in 20% to 40% of NSCLC [20,21].
It has been suggested that epigenetic changes might addict
cells to certain oncogenic pathways, predisposing cells to
the accumulations of genetic mutations, which drives
tumor progression [22]. On the other hand, overexpres-
sion of the K-ras gene can affect the activity of methytrans-
ferase [23,24] and potentially the methylation activity and
regulation of gene transcription. Several studies have indi-
cated the presence of an association between RASSF1 and
Ras proteins. For instance, Ras binds RASSF1C in a GTP-
dependent manner to mediate apoptosis [25]. Because
RASSF1A  has the identical Ras associate domain as
RASSF1C [15,16], RASSF1A may bind Ras in the same
manner as RASSF1C. Furthermore, Ras may also promote
apoptosis through its association with a Nore-RASSF1-Mst
1 complex [26,27] since RASSF1A was found to be the
closest Ras effector homologue to Nore1 in mammalian
cells [15]. RASSF1A  forms heterodimers with Nore1
through its non-homologous NH2-terminal segments
and interacts with Ras [28]. Therefore, RASSF1A may serve
as a Ras effector to mediate apoptosis.
DAPK and p53 may interact to mediate apoptosis. Raveh
et al demonstrated that DAPK executes its anti-oncogenic
action through activation of p53 in a mechanism that
requires p19ARF [29] and failure to perform apoptosis may
result in tumorigenesis. Other studies showed that DAPK
may also exert its p53-mediated suppressive effects on
oncogenic transformation by imposing growth arrest,
apoptosis or both [30,31].
Although EGFR mutations have been found frequently in
lung tumors, the relationship between these mutations
and promoter methylation in these tumors has not been
well studied. EGFR is a 170 kDa trans-membrane glyco-
protein. When EGFR binds to specific ligands, multiple
signaling pathways are activated, including the RAS/RAF/
ERK/MAPK pathway, resulting in cell proliferation, and
the p13/AKT pathway [32]. Recently, it has been demon-
strated that mutations in the tyrosine kinase domain
region of the EGFR gene in NSCLC predict the response to
tyrosine kinase inhibitors [33,34] and enable the identifi-
cation of the subpopulation of lung cancers that are likely
to respond to drugs targeted to EGFRs. The EGFR muta-
tions were found consistently more common in never-
smokers [5-7], indicating different pathways for lung tum-
origenesis between smokers and never-smokers. Although
both genetic and epigenetic alterations in oncogenes and
tumor suppressor genes have been identified frequently in
lung tumors, the interaction among these gene alterations
and their significance in lung cancer remains poorly
understood. In this study, we analyzed methylation in the
promoter region of the RASSF1A and DAPK genes in 122
lung cancer patients. We compared the results with those
reported by previous studies and with the status of muta-
tions in the K-ras, p53 and EGFR genes in the same lung
tumors obtained from patients from the Western Pennsyl-
vania region.BMC Cancer 2007, 7:74 http://www.biomedcentral.com/1471-2407/7/74
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Methods
Lung tumor tissues analyzed in this study were obtained
from 122 lung cancer patients, including 81 smokers and
41 never-smokers, all of whom were Caucasian and lived
in the Western Pennsylvania region. All 122 tumors were
among specimens collected between 1988 and 2001 and
stored at the University of Pittsburgh Medical Center
under an Institutional Review Board-approved protocol.
The demographic and clinical profiles of these patients are
shown in table 1. Of the 122 patients, 120 had NSCLC
while 2 had SCLC, including one patient with carcinoid
and one patient with neuroendocrine carcinoma. Most of
the never-smokers were females (31/41, or 75.6%) while
male patients accounted for 24.4% (10/41). The male and
female patients among the smokers were 51.9% (42/81)
and 48.1% (39/81), respectively.
Each lung tumor was histologically examined by a pathol-
ogist to identify the type and other clinical characteristics
of the tumor. Any contamination of tumor cells by non-
tumor cells was described by the pathologist. Most of the
cells in these lung tumor samples were tumor cells. DNA
was extracted from fresh-frozen tissues, using the Protein-
ase K treatment and phenol/chloroform method, and was
dissolved in distilled water and stored at -20°C until use.
Methylation-specific PCR (MSP)
Each genomic DNA sample was treated with sodium
bisulfite (Sigma, Saint Louis, MO) and purified by using a
Wizard DNA Clean-Up System (Promega Corporation,
Madison, WI), as described previously [12]. Universal
methylated human DNA (Chemicon International,
Temecula, CA) was treated the same way and was used as
a positive control DNA, and water was used as blank con-
trols.
Two versions of MSP have been previously reported,
including an original 1-stage MSP [35], and a modified 2-
stage MSP that used 2 rounds of PCR and had a higher
level of sensitivity to detect promoter methylation, com-
pared with the original 1-stage MSP [36]. We first com-
pared the sensitivity and validity of both MSP methods to
analyze promoter methylation of these genes in DNA
from some lung tumors. The results showed that pro-
moter methylation was detected in the same tumors and
at a similar frequency by using either the original or mod-
ified MSP for these genes, suggesting that the original 1-
stage MSP was sufficiently sensitive to detect promoter
methylation in lung tumors. However, in our experi-
ments, the 2-stage MSP method showed MSP-products as
one clear single band by gel electrophoresis analysis,
while the 1-stage MSP method provided products that
usually appeared with other minor bands (data not
shown). Therefore, in this study, we applied a sensitive
modified 2-stage MSP. The nucleotide sequences of the
primers used for MSP analysis for both the RASSF1A and
DAPK were the same as described by Belinsky et al [37].
During the stage-I PCR, the PCR amplification was carried
out in a 25-μl reaction mixture containing 10 mM Tris-
HCL (pH 8.3), 50 mM KCL, 2 mM MgCl2, 100 μM each
dNTP, and 0.2 μM each primer. The reaction was heated
at 95°C for 10 min., then amplified for 40 cycles [95°C/
30 sec., 64°C (for RASSF1A) or 58°C (for DAPK)/30 sec.,
and 72°C/30 sec.], followed by a 10-min.-final extension
at 72°C. Three microliters of each stage-I PCR product was
diluted 10-fold with water and 1-μl was used for stage-II
PCR, using the same reagents and conditions as for stage-
I, except that the MgCl2 concentration was reduced to 1
mM and each sample was amplified in duplicated reac-
tion, with one reaction containing primers specific for a
methylated C and the other reaction containing primers
specific for unmethylated C. Each reaction was heated at
95°C for 10 min., then amplified for 40 cycles each con-
sisting, for the reaction containing methylated primers, of
95°C/30 sec., 68°C (for RASSF1A) or 66°C (for DAPK)/
30 sec., and 72°C/30 sec., and, for the reaction containing
unmethylated primers, of 95°C/30 sec., 64°C (for
RASSF1A) or 68°C (for DAPK)/30 sec., and 72°C/30 sec.,
followed by a 10-min.-final extension at 72°C. Five
microliters of each stage-II PCR product was separated on
an 8% polyacrylamide gel. The gel was stained with ethid-
ium bromide and photographed under UV illumination.
The reproducibility of the results was confirmed by repeat-
ing the MSP analysis for each DNA sample. A portion of
PCR products were purified using a MinElute PCR purifi-
cation kit (QIAGEN, Valencia, CA) and directly sequenced
to confirm methylation.
Detection of K-ras, p53, and EGFR mutations
Data on mutations in K-ras  (codons 12 and 13), p53
(exons 5 – 8), and EGFR  (exons 18–21) genes were
obtained from our previous studies [2,38,39].
Statistical analysis
Chi-square test or Fisher's exact test was used in univariate
analysis. Logistic regression models were used to assess
the effect of multiple variables on methylation status and
relationship between genetic and epigenetic alterations.
Results
Overall, RASSF1A promoter methylation was detected in
46.7% (57/122) of the patients, a frequency that did not
differ between smokers and never-smokers [48.1% (39/
81) vs. 43.9% (18/41), p = 0.645], or between adenocar-
cinoma and the group of other tumor types [51.4% (37/
72) vs. 40% (20/50), p = 0.210], or between stage-I and
the group of other stages [51.9% (28/54) vs. 40.7% (22/
54), p = 0.247]. Promoter methylation for DAPK  was
found in 32.8% (40/122) of the patients. When grouped
according to the patient's smoking status, this gene meth-BMC Cancer 2007, 7:74 http://www.biomedcentral.com/1471-2407/7/74
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ylation was detected in 34.6% (28/81) of the smokers and
was not significantly different from the 29.3% (12/41)
frequency observed among the never-smokers (p =
0.567). Furthermore, DAPK  promoter methylation fre-
quency did not differ between adenocarcinoma and the
group of other tumor types [34.7% (25/72) vs. 30% (15/
50), p = 0.583], or between stage-I and the group of other
stages [31.5% (17/54) vs. 31.5% (17/54), p = 1.000].
Multivariate logistic regression models were employed to
control for the potential confounding effects of variables,
such as age, gender, smoking status, tumor histology and
tumor stage on methylation status of RASSF1A and DAPK
genes. As shown in Table 2, age, gender, and smoking sta-
tus did not significantly affect the methylation frequency
of the RASSF1A or DAPK gene. Promoter methylation of
RASSF1A  was associated significantly with adenocarci-
noma [the group of other tumor types vs. adenocarci-
noma: odds ratio (OR) = 0.661, 95% confidence interval
(CI) = 0.454–0.962, p = 0.031], and marginally with early
tumor stage (the group of other stages vs. stage-I: OR =
0.673, 95% CI = 0.444 – 1.022, p = 0.063). Neither tumor
histology nor tumor stage was associated with DAPK pro-
moter methylation.
Among the 122 patients, 32 (26.2%) had p53 mutations
whereas 90 (73.8%) had wild-type p53  [38]. The fre-
quency of RASSF1A  promoter methylation in patients
with p53 mutations was 56.3% (18/32) and was not sig-
nificantly different from that in patients with wild-type
p53 [43.3% (39/90), p = 0.212]. Likewise, the DAPK pro-
moter methylation frequency in patients with p53 muta-
tions was 25% (8/32) and not different from that in
patients with wild-type p53 [35.6% (32/90), p = 0.331].
Thirty-six (29.5%) of the 122 patients had K-ras muta-
tions and 86 (70.5%) had wild-type K-ras [2]. Among the
K-ras  mutation-positive patients, the frequency of
RASSF1A promoter methylation was 41.7% (15/36) and
was closely similar to the 48.8% (42/86) frequency in the
group of patients with wild-type K-ras (p = 0.474). Like-
wise, the frequency of DAPK promoter methylation was
closely similar between the K-ras  mutation-positive
patients and patients with a wild-type K-ras [30.6% (11/
36) vs. 33.7% (29/86), p = 0.735].
Data for EGFR mutations were obtained from a previous
study [39] and were available for only 70 of the 122
patients involved in this study, including 40 never-smok-
ers and 30 smokers. EGFR mutations were detected in
14.3% (10/70) of the patients and exclusively among the
never-smokers (10/40, or 25%), including 9 females and
one male, and none among the smokers (p = 0.002), and
inversely correlated with K-ras mutations [0% (0/10) vs.
28.3% (17/60), p = 0.049], in agreement with previous
reports [6,7,13,40]. For comparison, EGFR  mutations
were found in both tumors with p53 mutations and those
without these mutations [30% (3/10) vs. 28.3% (17/60),
p = 0.912], suggesting that, unlike K-ras mutations, p53
mutations can occur in concert with EGFR mutations, in
Table 1: Demographic and clinical profile of 122 NSCLC patients
Variable cases (%)
Age (mean ± s.d.*) 65.1 ± 10.2
Gender
Male 52 (42.6)
Female 70 (57.4)
Smoking status
Smoking 81 (66.4)
Never-smoking 41 (33.6)
Tumor types
Adenocarcinoma 72 (59.0)
Squamous cell carcinoma 22 (18.0)
Bronchioloalveolar carcinoma 15 (12.3)
Adenosquamous carcinoma 9 (7.4)
Large cell carcinoma 2 (1.6)
Carcinoid 1 (0.8)
Neuroendocrine 1 (0.8)
Tumor stage
I 54 (44.3)
II 24 (19.7)
III 19 (15.6)
IV 11 (9.0)
Unknown 14 (11.5)
*: standard deviationBMC Cancer 2007, 7:74 http://www.biomedcentral.com/1471-2407/7/74
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agreement with Kosaka's report (p = 0.4634) [6]. EGFR
mutations did not correlate with promoter methylation of
RASSF1A or DAPK (data not shown).
Of the 122 patients, 100 (81.9%) showed alterations of at
least one gene, consisting of either promoter methylation
of RASSF1A or DAPK, or mutations in the K-ras or p53
gene. Furthermore, since K-ras  mutations were found
mostly among smokers, smoking patients showed a
higher fraction of tumors with gene alterations, compared
with the never-smoking patients [87.6% (71/81) vs.
70.7% (29/41), p = 0.022]. Of the 100 patients with alter-
ations of at least one gene, 46 (46%), 43 (43%), and 11
(11%) showed alterations affecting one gene, two genes,
and three or more genes, respectively. The frequency of
cases with more than one gene abnormality did not differ
between adenocarcinoma and the group of other tumor
types, or between stage I and the group of other stages
(data not shown). The EGFR mutations were not included
in the calculation because they were available for only 70
of the 122 patients.
Discussion
The overall frequency of RASSF1A promoter methylation
of 46.7% (57/122) in our study is similar to that found by
Marsit et al [47% (83/178)] [17] and correlated signifi-
cantly with adenocarcinoma (p = 0.031, table 2), in agree-
ment with some previous studies [11,17,41], and
marginally with tumor stage (p = 0.063, table 2). On the
other hand, studies by Kim et al showed no such an asso-
ciation [42,43].
The overall frequency of DAPK promoter methylation of
32.8% (40/122) found in the present study is in line with
that reported by Toyooka's 37% (14/38) [44] and was not
associated with tumor histology (p = 0.111, table 2), in
agreement with Kim's study [21], or with tumor stage (p =
0.348, table 2). Data from previous studies are conflicting.
For instance, in Kim's study DAPK promoter methylation
was associated with advanced stages NSCLC (p = 0.009)
[21], whereas in Russo's study it was detected mostly in
early stages NSCLC [45]. This discrepancy might be due to
limited number of patients in Russo's study (n = 49) and/
or tumor stage data that were not available for some
patients in our study. The frequencies of both RASSF1A
and DAPK gene promoter methylation were independent
from the patients' smoking status (p = 0.990 for RASSF1A
and p = 0.275 for DAPK, table 2), consistent with the
results of previous studies [10,11,41,46].
There have been a few studies investigating the relation-
ship between aberrant promoter methylation and muta-
tions in oncogenes and tumor suppressor genes. Most of
these studies compared promoter methylation of one or
two genes with mutations in either the K-ras or p53 gene
[41,43,46]. Only two recent studies investigated the rela-
tionship between mutations of multiple oncogenes and/
or tumor suppressor genes and promoter methylation pat-
terns but in lung cancer patients from Japan [13,40]. Here,
we compared the promoter methylation status of
RASSF1A  and  DAPK  and mutations of K-ras,  p53  and
EGFR in the same lung tumors from lung cancer patients
from the Western Pennsylvania region.
We observed no association of RASSF1A gene promoter
methylation frequency with that of K-ras mutations (p =
0.474), in agreement with previous studies [11,41,43,46],
or with the types of amino acid changes at codon 12 of the
K-ras gene (data not shown). Activated Ras has been asso-
ciated with enhanced proliferation, transformation, and
cell survival through a series of effectors, including
RASSF1A. However, because the RASSF1A gene is a tumor
suppressor gene, it is likely that loss of RASSF1A expres-
sion by promoter methylation in NSCLC does not require
Ras activation. Thus, our findings suggest that RASSF1A
inactivation may induce malignant transformation by
some distinct mechanisms other than Ras-mediated anti-
apoptosis pathway, such as loss of genomic, microtubule
stability and cell cycle regulation [14]. Furthermore, the
prevalence of DAPK promoter methylation did not corre-
late with that of K-ras mutations (p = 0.735), consistent
with previous data [11,21], suggesting that DAPK  pro-
Table 2: Logistic regression models of DAPK and RASSF1A promoter methylation (n = 122)
DAPK RASSF1A
OR (95% CI) p OR (95% CI) p
Age 1.022 (0.977–1.068) 0.352 1.003 (0.964–1.045) 0.872
Sex 1.911 (0.746–4.894) 0.177 1.203 (0.513–2.822) 0.671
Smoking 1.743 (0.642–4.732) 0.275 1.006 (0.410–2.469) 0.990
Histology† 0.709 (0.465–1.082) 0.111 0.661 (0.454–0.962) 0.031
Stage‡ 0.804 (0.509–1.269) 0.348 0.673 (0.444–1.022) 0.063
OR: odds ratio; CI: confidence interval.
†: the group of other tumor types vs. adenocarcinoma.
‡: the group of other stages vs. stage I.BMC Cancer 2007, 7:74 http://www.biomedcentral.com/1471-2407/7/74
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moter methylation and K-ras mutations are independent
events in non-small cell lung tumorigenesis.
The prevalence of RASSF1A promoter methylation in the
present study did not correlate with that of p53 mutations
(p = 0.212). Previously, Endoh et al found a similar trend
in their study of 100 NSCLC patients (21/56 wild-type p53
vs. 21/44 mutant p53, p = 0.3165) [41]. On the other
hand, Tomizawa et al observed a weak association
between RASSF1A promoter methylation and p53 muta-
tions (19/73 wild-type p53  vs. 16/37 mutant p53, p =
0.0842) [46]. The discrepancy may be in part due to the
difference in tumor stages in the different studies, with all
patients in stage I lung adenocarcinoma tumors in Tomi-
zawa's study and a mixed of tumors of different types
[adenocarcinoma: 67% (67/100) and 59% (72/122)] and
stages [stage I: 57% (57/100) and 44% (54/122)] in
Endoh's and our studies.
We observed no correlation between the prevalence of
DAPK methylation and that of p53 mutations (p = 0.331),
indicating DAPK promoter methylation and p53 muta-
tions may be independent events in NSCLC. DAPK, and a
few other genes, have been reported to operate upstream
to p53 to induce apoptosis. For instance, Raveh et al found
that the inactivation or loss of DAPK alone significantly
reduces but not completely eliminates p53 in response to
c-Myc or E2F-1 [29]. Kim et al found that DAPK promoter
methylation and p53 mutations were not related in their
study of 185 NSCLC patients (p = 0.85) [21]. Thus, our
results are consistent with those of these studies [21,29],
suggesting that DAPK may be wired simultaneously to a
few independent upstream branches of p53, and may be
involved in apoptosis without p53 participation.
Results of our study based on 70 patients showed that
EGFR mutations did not correlate with the RASSF1A or
DAPK gene promoter methylation. Previously, there are
only two studies investigating the relationship of
RASSF1A  promoter methylation and EGFR  mutation,
reporting absent [13] or borderline [47] correlation
between these two events. The relationship between these
mutations and DAPK promoter methylation has not been
previously investigated. Furthermore, there have been
only two previous studies of epigenetic and genetic alter-
ations in multiple genes in lung tumors, both involving
lung cancer patients from Japan. In the study by Toyooka
et al [13], mutations in the EGFR and K-ras genes were
compared with promoter methylation of five genes in
lung adenocarcinomas from 164 patients. There was no
significant association between RASSF1A promoter meth-
ylation frequency and the K-ras or EGFR mutation fre-
quency. Our data are in agreement with this finding. In
the study by Suzuki et al [40], EGFR, HER-2, and K-ras
mutations were compared with promoter methylation of
nine genes in 150 NSCLC patients. The authors observed
that EGFR mutation had an inverse correlation with pro-
moter methylation of the secreted protein acidic and rich
in cysteine and p16 genes. However, K-ras mutations were
detected at a lower fraction of the tumor, compared with
our study (6 out of 150 versus 36 out of 122) and was not
investigated in relation to RASSF1A methylation.
The relationship between epigenetic and genetic altera-
tions has also been investigated in other tumor types. For
instance, in sporadic colorectal cancer and pancreatic can-
cer, RASFF1A promoter methylation was found predomi-
nantly in tumors with K-ras wild type [48,49]. Another
study showed that sporadic colorectal cancer exhibiting
microsatellite instability harbored concomitant RASSF1A
gene promoter methylation and mutations in the K-ras
and/or B-raf genes [50].
Taken together, results from these studies and our present
study indicated the need for further investigation of the
interaction between genetic and epigenetic alterations in
lung tumors in an ethnically diverse patient population in
order to further understand the development of lung can-
cer.
Conclusion
Promoter methylation of the RASSF1A and DAPK genes
was frequent in lung tumors from patients with primarily
NSCLC, all of whom were Caucasian and from the West-
ern Pennsylvania region. Furthermore, there was a signif-
icant association between promoter methylation of the
RASSF1A gene and tumor histology, specifically adeno-
carcinoma. However, there was no significant association
of the prevalence of promoter methylation of either gene
with the smoking status of the patients or with the status
of mutations in the K-ras, p53, or EGFR gene, suggesting
Detection of RASSF1A and DAPK promoter methylation by  MSP Figure 1
Detection of RASSF1A and DAPK promoter methyla-
tion by MSP. M indicates the presence of methylated 
RASSF1A or DAPK. U indicates the presence of unmethylated 
RASSF1A or DAPK. All samples were performed twice and 
representative data are shown.
1516T       1788T      1355T     1554T     1734T        H2O        control
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U    M       U    M     U     M    U     M     U M      U M      U     M
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each of these events may occur independently in lung
tumorigenesis.
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